ASPEGIC: Aspects of Vulnerability of People Living With HIV in the Alpine Arc Region

Sponsor
Centre Hospitalier Annecy Genevois (Other)
Overall Status
Recruiting
CT.gov ID
NCT04846595
Collaborator
(none)
600
1
1
22.4
26.7

Study Details

Study Description

Brief Summary

HIV infection in France has become a chronic disease and treatment has allowed patients to increase their life expectancy. However, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. Few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. The investigators chose to consider the vulnerability of people living with HIV (PLWHA) through the measurement of a validated French quantitative score, called EPICES ("Évaluation de la précarité et des inégalités de santé dans les centres d'examens de santé ", Evaluation of precariousness and health inequalities in health examination centers).

Condition or Disease Intervention/Treatment Phase
  • Other: self questionnaire
N/A

Detailed Description

HIV infection in France has become a chronic disease and treatment has allowed patients to increase their life expectancy. However, these promising results suffer from a very large variability within the socio-epidemiological subgroups, and life expectancy at 20 years of age is still one third lower than in the general population. Few studies of metropolitan cohorts investigated precariousness as an independent risk factor for mortality. The investigators chose to consider the vulnerability of people living with HIV (PLWHA) through the measurement of a validated French quantitative score, called EPICES (Evaluation of precariousness and health inequalities in health examination centers). Using a self-administered questionnaire administered during an annual follow-up visit to an infectious disease specialist, the investigators seek to define in the alpine arc region in france, socio-demographic data associated with greater precariousness among PLWHA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Aspects of Vulnerability of People Living With HIV in the Alpine Arc Region
Actual Study Start Date :
Feb 16, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Self questionnaire

The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.

Other: self questionnaire
Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region

Outcome Measures

Primary Outcome Measures

  1. Variables of vulnerability [one day]

    Evaluation of the variables associated with a state of vulnerability according to the "EPICES" scale (at a threshold of 30.17/100), among the social, demographic and medical characteristics of people living with HIV in the Alpine Arc region characteristics of people living with HIV in the Alpine Arc region

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any person living with HIV presenting for consultation with their infectious disease referrer.

  • Patient followed for at least 6 months for their HIV infection

  • Patient with undetectable or detectable HIV viral load

  • Patient of legal age at the time of the study

  • Patient informed of the study and having expressed no objection to the collection of health data

Exclusion Criteria:
  • Patient opposed or unable to express opposition to participation in the study

  • Patient is a minor at the time of the study

  • Patient taking antiretroviral therapy for less than 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ch Annecy Genevois Pringy Haute-Savoie France 74374

Sponsors and Collaborators

  • Centre Hospitalier Annecy Genevois

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Annecy Genevois
ClinicalTrials.gov Identifier:
NCT04846595
Other Study ID Numbers:
  • 20-16
First Posted:
Apr 15, 2021
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022